Her2neu Breast Cancer - Mayo Clinic Rochester MN

At the Forefront of Immunotherapy

OTCQB: TPIV

1551 Eastlake Ave E

Suite 100

Seattle, WA www.TapImmune.com

CAUTIONARY STATEMENT REGARDING

FORWARD LOOKING STATEMENTS

Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of

1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company's plan of operations and finances, the potential for the Company's vaccines and proposed clinical trials.

The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof.

TAPIMMUNE INC.

A New Frontier in Immunotherapy

TapImmune is an Immunotherapy company specializing in the development of the most comprehensive and innovative

immunotherapeutics in cancer and infectious diseases.

Opportunity & Milestones

Why invest in TapImmune now?

• Unique and Broad product opportunities in cancer & infectious disease

• Two Phase I Clinical Trials ready to progress to Phase II

• HER2/neu breast cancer vaccine potential blockbuster

• Ovarian Cancer Urgently Needed Therapeutic with blockbuster potential

• HUGE market opportunities in multiple therapeutic indications

• PolyStart™ expression vector is a significant advance in vaccine technologies

• Strong management & advisory team

• Leverage of key collaborations with leading institutions

• Series of preclinical and clinical value inflexion points

• Significantly undervalued and poised for significant growth

An approach with the potential to change lives and excellent entry level valuation

TAPIMMUNE

Harnessing the Power of Immune System

Leading Immunotherapy Approach:

CANCER

• Making tumors visible to T-cells

• Stimulating T-killer cells AND T-helper cells

• Applicable to broad patient populations

INFECTIOUS DISEASE

• Up-regulation of Antigen Presentation

• Stimulating T-killer cells & T-helper cells

• Applicable Multiple Infectious Diseases and Biothreats

The Immunotherapy Space

New Frontier in Treatment of Cancer

Immunotherapies

Immune Checkpoint Blocade, Monoclonal antibodies (Roche) T-cell

Therapies

T-Cell Therapies

Ex-Vivo: Adoptive T-cell transfer (LBIO;Juno); Dendritic cell transfer

(NWBIO;DNDN; PBMD)

In Vivo: Antigen stimulation (ONTY;GALE;IMUC)

TapImmune is Unique:

Platforms to stimulate BOTH Antigen presentation & T Cell stimulation

(TPIV)

GOAL: To Stimulate the Immune System to Effectively KILL

Tumors

The TapImmune Approach

Why we are different!

Prime BOTH sides of the tumor Killing equation

Proprietary peptide antigens used to stimulate a broad based

• T - Helper cell response (CD4) LONG-LIVED

• KILLER T-cells to actually KILL the tumor (CD8)

These Proprietary Antigens allow us to treat:

• Wider patient populations (EG: +50% Vs Roche Herceptin 15%)

• Multiple Indications

• Multiple Therapeutic Areas (Cancer and Infectious Disease)

SOLUTION: Most COMPREHENSIVE immunotherapeutic in development

Product Pipeline

Clincal Trial - Breast

TPIV100/110

Trial 1: Her2neu Breast Cancer - Mayo Clinic Rochester MN

• HER2/neu positive breast cancer is one of most aggressive forms

• HER2/neu is overexpressed in ~ 30% breast cancer patients (total

220,000 /yr)

• Roche’s monoclonal antibody, Herceptin (current standard of care) can only treat ~ 20% of these patients (+$6 billion sales in 2013)

• Herceptin does not stimulate Killer T-cells – it slows/retards tumor growth

In Contrast: We believe TapImmune’s comprehensive combination of

Killers and Helpers has the potential to provide Long Lasting Immune

Response in upto 84% of the HER2/neu positive patient population.

• A $ Multi-Billion product potential meeting an UNSATISFIED CLINICAL

NEED in a very LARGE Market

Herceptin Facts:

Late Stage Survival improved by 4.5 Months.

Early stage treatment resulted in a 9.5% improvement on recurrence.

70% of Her2neu+ patients do NOT respond to treatment

HER2/neu Clinical Status

Her2neu Breast Cancer - Mayo Clinic Rochester MN

Phase l

Phase lb/ll

• Class II antigens (4 epitopes NPE) discovered in breast cancer patients - Clin. Cancer Res. (2010) 16, 825-83

• 22 Patients post Herceptin

• 6 x monthly intradermal + GMCSF

 Interim safety chectkpoint completed

 Positive Immune responses on first 6 patients (interim data)

• Excellent Results – Support progression to Phase ll

Class II + Class I (p373-382) antigens (4+1)

• To start Q4, 2014

• Small safety study

• 100-150 patient multicenter phase II

ImmunoTherapeutic TPIV110

Most Comprehensive Her2neu Breast Cancer Immunotherapeutic

Leading HER2/neu Vaccine Candidate in Development

Peptide Antigens to stimulate BOTH:

• T-helper cells – Long Lasting

• Antigens discovered in breast cancer patients

• Naturally Processed Epitopes (NPE’s)

• Killer T-cells (p373-382) - Kills Tumor Cells

Compared to NeuVax by Galena:

4-5x greater KILLING activity against human tumor cell targets

See: J.Immonol. (2013) 190, 479-488

Clinical Trial Ovarian

TPIV200

Trial 2: Stage II/IIl Ovarian & Breast Cancer - Mayo Clinic MN

• Folate Receptor Alpha is expressed over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy

• Very important and urgent clinical need for a new therapeutic.

• Time to recurrence is relatively short for this type of cancer and survival prognosis is extremely poor after recurrence.

• US alone, approximately 30,000 ovarian cancer patients newly diagnosed every year.

• Phase lb/2 advancement expected in late 2014.

• Orphan Drug Application – Pending FDA

• Another $ Multi-Billion product potential with an UNSATISFIED CLINICAL

NEED

URGENT CLINICAL NEED – LARGE MARKET – ORPHAN DRUG – FAST TRACK?

Clinical Trial Ovarian

TPIV200

Trial 2: Stage II/IIl Ovarian & Breast Cancer - Mayo Clinic MN

23 patients with Stage II-III Breast, Ovarian, Peritoneal, Fallopian

Tube Cancer

 Interim safety checkpoint completed

 Positive Immune responses observed

Promising Interim Results – Support progression to Phase ll

Phase ll Expected to Start in 2014 with Orphan Drug Application - FDA Pending

These Folate Alpha Antigens Also Applicable to Triple Negative Breast Cancer

Collaborators & Scientific Advisors

World Class Team

Dr Keith Knutson (Vaccine & Gene Therapy Institute of Florida/Mayo Clinic):

Director, Cancer Immunology and Immunotherapy Program, VGTI;

Adjunct Faculty - Immunology, Mayo Clinic

Dr Greg Poland: (Mayo Clinic)

Head of Vaccines; Infectious disease/biodefense

Dr Mac Cheever (Fred Hutchinson Cancer Research Center)

Director Solid Tumor Research; Professor of Medicine/Oncology at the University of

Washington (Seattle) & Director of the NCI-funded Cancer Immunotherapy Trials

Network (CITN)

Mark Reddish Advisor: Development , Board

Product Development: Cancer vaccines and Biodefense: Biomira, ID Biomedical, Baxter,

Bayer AG

Management And Advisors

Glynn Wilson, PhD

CEO

25 years experience in product & corporate development

SmithKline Beecham,

Ciba-Geigy, Tacora

Denis Corin

Corporate Finance

Beckman Coulter,

Novartis, MIV

Therapeutics, Business

Objects (PeopleSoft)

Bob Florkiewicz,

PhD

Head of Research

25 years experience, academic and biotech

Synergen, TSRI, UW, GSK,

Seed IP Law Group

Mark Reddish

Advisor: Development,

Board

25 years experience in cancer vaccines and biodefense

Biomira, ID Biomedical, Baxter,

Bayer AG

Cap Structure and Comps

Reorganized Feb 2014

TPIV - TAPIMMUNE INC

Capital Structure

Shares Outstanding

Public Float

Market cap

Stock Price

19,000,000

6,000,000

~$25,000,000

$1.25

Comparrisons in Immunotherapy and Biotech

GALE (Galena)

Shares Out

105,240,000

LBIO (Lion Bio)

INO (Inovio)

DNDN (Dendreon)

NWBO (Nothwest Bio)

26,000,000

60,000,000

160,000,000

53,400,000

Market Cap

$ 250,000,000

$ 180,000,000

$ 565,550,000

$ 636,560,000

$ 355,730,000

Stock Price

$2.50

$6.50

$10.30

$1.40

$5.95

Opportunity & Milestones

Why invest in TapImmune now?

• Unique and Broad product opportunities in cancer & infectious disease

• Two Phase I Clinical Trials ready to progress to Phase II

• HER2/neu breast cancer vaccine potential blockbuster

• Ovarian Cancer Urgently Needed Therapeutic with blockbuster potential

• HUGE market opportunities in multiple therapeutic indications

• PolyStart™ expression vector is a significant advance in vaccine technologies

• Strong management & advisory team

• Leverage of key collaborations with leading institutions

• Series of preclinical and clinical value inflexion points

• Significantly undervalued and poised for significant growth

An approach with the potential to change lives and excellent entry level valuation

THANK YOU

CONTACT:

GLYNN WILSON

Chief Executive Officer gwilson@tapimmune.com

DENIS CORIN

Corporate Finance dcorin@tapimmune.com

OTCBB: TPIV